Skip to main content
. 2022 Sep 28;15:1067–1078. doi: 10.2147/OTT.S379591

Figure 2.

Figure 2

Kaplan-Meier estimates of progression-free survival. (A) Survival analysis for all patients (n=171). (B) Survival analysis according to ECOG PS. (C) Survival analysis according to the lines of pyrotinib-based therapy. (D) Survival analysis according to the status of HR and HER2. P-values are from univariate Log rank tests.